乳腺癌组织及间质浸润淋巴细胞中PD-L1的表达及其意义  

Expression and significance of PD-L1 in breast cancer tumor cells and tumor-infiltrating lymphocytes

作　　者：黄述斌[1] 侯永微[1] 李松梅[1] 王志强[1] 徐亮[1] 王海平[1] 

机构地区：[1]安徽省池州市人民医院病理科,247100

出　　处：《临床与实验病理学杂志》2017年第1期63-67,共5页Chinese Journal of Clinical and Experimental Pathology

摘　　要：目的探讨程序性死亡配体-1(programmed death ligand-1,PD-L1)在乳腺癌组织及间质浸润淋巴细胞(stromal tumor-infiltrating lymphocyte,sTIL)中的表达及其与临床病理特征的关系。方法收集68例乳腺非特殊性浸润性癌,采用免疫组化EliVision两步法检测PD-L1蛋白表达,并分析其与免疫组化亚型及临床病理特征的关系。结果乳腺肿瘤细胞中PD-L1总阳性率为35.3%,尤其在三阴型乳腺癌肿瘤细胞中的阳性率最高,在管腔型、HER-2过表达型及三阴型乳腺癌肿瘤细胞中的阳性率分别为16.1%、37.5%、61.9%,差异有统计学意义。PD-L1在sTIL中的总阳性率为51.5%,且在三阴型乳腺癌中最高,阳性率为81.0%;PD-L1在管腔型、HER-2过表达型及三阴型乳腺癌sTIL中的表达差异具有统计学意义。PD-L1在乳腺癌与sTIL中的表达呈正相关。结论 PD-L1在三阴型乳腺癌中表达明显高于其他类型乳腺癌,阻断PD-L1/PD-1信号通路,有望成为乳腺癌尤其是三阴型乳腺癌免疫治疗的新策略。Purpose To investigate the expression of pro- grammed death ligand-1 （ PD-L1 ） in breast cancer tumor cells and stromal tumor-infiltrating lymphocyte （ sTIL）, and to study the relationship between the expression of PD-L1 and the clinico- pathological characteristics of the patients. Method The pro- tein expression of PD-L1 was detected by immunohistoehemistry of EliVision two-step method in 68 cases of non special type of invasive breast cancer, and the relationship between the expres- sion of PD-L1 protein and the immunohistochemistry subtypes and clinical parameters was analyzed. Results The total ex- pression rate of PD-L1 was 35.3% in breast tumor tissue, spe- cially in triple negative breast cancer （TNBC） which occupy the highest positive rate. The expression rates of PD-L1 in tumor tis- sue of the luminal subtype, HER-2 over-expression subtype and TNBC subtype were 16.1%, 37.5% and 61.9% respectively, and the difference was statistically significant. The total expres- sion rate of PD-L1 in sTIL was 51.5%, and the highest expres- sion rate was 81.0% in TNBC. There were significant differ- ences of PD-L1 expression in sTIL of the luminal subtype, HER- 2 over-expression subtype and TNBC subtype. Expression of PD- LI in tumor tissue and sTIL had a significant positive correla- tion. Conclusion PD-L1 expressed in TNBC was significantly higher than other types of breast cancer, which suggest the bloc- king of signal pathway of PD-1/PD-L1 may expected to become a new immunotherapy for breast cancer, especially for TNBC sub- type.

关 键 词：乳腺肿瘤 免疫组化亚型 程序性死亡配体-1 免疫治疗 

分 类 号：R737.9[医药卫生—肿瘤]